Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SNTI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSenti Biosciences reports Q1 2026 results, announces SENTI-202 clinical and regulatory update
Filed May 14, 2026 · Period ending May 14, 2026 · ~1 min read
Key Changes
-
medium
Company disclosed clinical data and regulatory interactions for SENTI-202, its product in development. Specific details on trial outcomes or FDA feedback are in the press release, signaling potential program progress.
Item 8.01 verify on EDGAR → -
medium
Senti announced financial results for the quarter ended March 31, 2026. This is a routine quarterly earnings disclosure with detailed figures provided in the attached press release.
Item 8.01 verify on EDGAR →
Summary
Senti Biosciences issued two press releases on May 14, 2026, covering both its first quarter 2026 financial performance and an update on SENTI-202, a clinical-stage product candidate. The 8-K filing itself provides minimal detail, directing investors to the attached press releases for specifics on earnings figures and the nature of the clinical data or regulatory feedback received. For retail investors, the SENTI-202 update is the more significant disclosure, as clinical progress and regulatory interactions can materially affect the company's development timeline and valuation.
The quarterly earnings release is routine but important for tracking cash burn and runway. Watch for management commentary in the press releases about next steps for SENTI-202, including trial enrollment status, expected data readouts, or regulatory milestones that could drive near-term catalysts.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 14, 2026, Senti Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.
The company disclosed its financial results for the first quarter of 2026 ending March 31, 2026. The actual financial details are contained in the press release furnished as Exhibit 99.1, which is not included in this 8-K body. This is a routine quarterly earnings announcement.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 14, the Company issued a press release announcing certain clinical data and regulatory interactions related to its product SENTI-202.
Senti disclosed clinical data and regulatory interactions for SENTI-202, a product in development.2) for specifics. This type of disclosure typically signals progress or updates in a clinical program that management deemed material enough to announce publicly.
Event · Item 9.01 — Financial Statements and Exhibits
Senti Biosciences filed an 8-K attaching two press releases dated May 14, 2026; no material event details disclosed in the filing body.
Added in current filing · view on EDGAR →
99.1 Press Release, dated May 14, 2026
99.2 Press Release, dated May 14, 2026
The 8-K lists two press releases dated May 14, 2026 as exhibits. The filing body provides no details about the content or subject matter of these releases, so the nature and materiality of the disclosed events cannot be determined from this document alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify